Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia

• Published in: Critical care medicine Vol. 45; no. 2; p. e124
• Main Authors: Fitzgerald, Julie C, Weiss, Scott L, Maude, Shannon L, Barrett, David M, Lacey, Simon F, Melenhorst, J Joseph, Shaw, Pamela, Berg, Robert A, June, Carl H, Porter, David L, Frey, Noelle V, Grupp, Stephan A, Teachey, David T
• Format: Journal Article
• Language: English
• Published: United States 01.02.2017
• Subjects: Adolescent; Antibodies, Monoclonal, Humanized - therapeutic use; Child; Child, Preschool; Cytokines - metabolism; Female; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology; Receptors, Antigen, T-Cell - immunology; Receptors, Antigen, T-Cell - therapeutic use; Recombinant Fusion Proteins - therapeutic use; Recurrence; Retrospective Studies; Syndrome; Systemic Inflammatory Response Syndrome - chemically induced; Young Adult

Initial success with chimeric antigen receptor-modified T cell therapy for relapsed/refractory acute lymphoblastic leukemia is leading to expanded use through multicenter trials. Cytokine release syndrome, the most severe toxicity, presents a novel critical illness syndrome with limited data regardi...